| Literature DB >> 35199205 |
Kayo Tomimori1, Yuki Kodama1, Hiroyuki Tanaka2, Atushi Yamashita2, Toshihiro Gi2, Yujiro Asada2, Koutarou Doi1, Shinji Katsuragi1, Yuichiro Sato3.
Abstract
Transient abnormal myelopoiesis (TAM), also known as transient myeloproliferative disorder or transient leukemia, is a self-regressing neoplasia that afflicts infants with trisomy 21. A recent review article documented "myeloid cell thrombus (MCT)" and "fetal vascular malperfusion (FVM)" in placentas with TAM, although the characteristic TAM placental findings have not been clarified. Here, we compared the clinical and pathological placental findings between trisomy 21 patients with or without TAM. In 13 cases of trisomy 21, we identified six placentas with TAM and seven placentas without TAM. The six placentas with TAM included two stillborn cases. Microscopically, MCT was noted in all the cases, and a high incidence of FVM (50%) was observed in TAM cases. Immunohistochemically, MCT was found to be a platelet-rich thrombus. The placentas were grouped according to the presence or absence of TAM and subsequently compared. Clinically, the incidences of abnormal fetal heart rate pattern and fetal or neonatal death were significantly higher in TAM cases. Pathologically, placenta in TAM cases weighted more than those in cases without TAM, and the incidence of MCT was significantly higher in placentas with TAM. Moreover, the incidence of FVM was higher in placentas with TAM, but this difference was not statistically significant. We propose that MCT is a diagnostic feature of placentas with TAM and may be associated with poor fetal outcomes.Entities:
Keywords: Fetal vascular malperfusion; Myeloid cell thrombosis; Pathology; Placenta; Transient abnormal myelopoiesis
Mesh:
Year: 2022 PMID: 35199205 DOI: 10.1007/s00428-022-03289-5
Source DB: PubMed Journal: Virchows Arch ISSN: 0945-6317 Impact factor: 4.064